← Back to Search

Alkylating agents

Cetuximab for Lung Cancer

Phase 3
Waitlist Available
Led By Roy Herbst
Research Sponsored by Southwest Oncology Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must not have received prior chemotherapy for any stage non-small cell lung cancer; patients must not have received prior platinum-based chemotherapy for any purpose; patient must not have received any cetuximab, gefitinib, erlotinib, or other investigational agents that target the EGFR pathway; patients must not have received for any purpose prior bevacizumab or other vascular endothelial growth factor (VEGF)-related agents; patients must not have received for any purpose prior chimerized or murine monoclonal antibody therapy or have documented presence of human anti-mouse antibodies (HAMA)
Prior radiation is permitted; however, patients must have recovered from all associated toxicities at time of registration; in order to qualify as measurable, measurable disease must be outside the previous radiation field or must have progressed
Timeline
Screening 3 weeks
Treatment Varies
Follow Up disease assessment will be repeated every 6 weeks for the first 9 months and every 3 months thereafter, until disease progression.
Awards & highlights

Study Summary

This trial is testing carboplatin, paclitaxel, bevacizumab, and cetuximab to treat patients with stage IV or recurrent non-small cell lung cancer.

Eligible Conditions
  • Large Cell Lung Carcinoma
  • Lung Cancer
  • Large Cell Lung Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~disease assessment will be repeated every 6 weeks for the first 9 months and every 3 months thereafter, until disease progression.
This trial's timeline: 3 weeks for screening, Varies for treatment, and disease assessment will be repeated every 6 weeks for the first 9 months and every 3 months thereafter, until disease progression. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Survival (OS) in the Entire Study Population
Progression-free Survival (PFS) of EGFR FISH-positive Patients by Institutional Review
Secondary outcome measures
Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
Overall Survival (OS) of EGFR FISH-positive Patients
Progression-Free Survival (PFS) of EGFR FISH-positive Patients by Centralized Review
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm II (chemo, cetuximab, +/- bevacizumab)Experimental Treatment5 Interventions
Patients receive paclitaxel and carboplatin with or without bevacizumab as in Arm I. Patients also receive cetuximab IV over 1-2 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients may continue to receive cetuximab with or without bevacizumab (as above) in the absence of disease progression or unacceptable toxicity.
Group II: Arm I (chemo +/- bevacizumab)Experimental Treatment4 Interventions
Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes with or without bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients receiving bevacizumab may continue to receive bevacizumab (as above) in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cetuximab
FDA approved
Bevacizumab
FDA approved
Carboplatin
FDA approved
Paclitaxel
FDA approved

Find a Location

Who is running the clinical trial?

Southwest Oncology GroupLead Sponsor
388 Previous Clinical Trials
260,918 Total Patients Enrolled
SWOG Cancer Research NetworkLead Sponsor
394 Previous Clinical Trials
264,277 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,609 Previous Clinical Trials
40,914,313 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

For what purpose is Bevacizumab most commonly prescribed?

"Bevacizumab is most frequently used to fight cancer, but it can also be employed as a treatment for conditions like locally advanced nonsquamous non-small cell lung cancer, intolerance to irinotecan, and metastatic colorectal cancer."

Answered by AI

Does Bevacizumab have a good safety profile?

"Bevacizumab has been studied in multiple clinical trials, so its safety rating is a 3."

Answered by AI

Are there any other similar studies to Bevacizumab that have been completed?

"City of Hope Comprehensive Cancer Center first studied bevacizumab in 1997 and, to date, there have been 3152 completed trials. Of these clinical studies, 1620 are active with many of them located in Silver Spring, Maryland."

Answered by AI

Who else is applying?

How old are they?
18 - 65
What site did they apply to?
University of California San Diego
California Pacific Medical Center-Pacific Campus
Wilcox Memorial Hospital and Kauai Medical Clinic
What portion of applicants met pre-screening criteria?
Met criteria
What state do they live in?
California
Recent research and studies
~85 spots leftby Mar 2025